CN104394872A - 用于治疗与癌症化学治疗剂的给药相关的副作用的组合物和方法 - Google Patents

用于治疗与癌症化学治疗剂的给药相关的副作用的组合物和方法 Download PDF

Info

Publication number
CN104394872A
CN104394872A CN201380031029.XA CN201380031029A CN104394872A CN 104394872 A CN104394872 A CN 104394872A CN 201380031029 A CN201380031029 A CN 201380031029A CN 104394872 A CN104394872 A CN 104394872A
Authority
CN
China
Prior art keywords
administration
compositions
orotate
adenine
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380031029.XA
Other languages
English (en)
Chinese (zh)
Inventor
J·P·福特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asymmetric Therapeutics LLC
Original Assignee
Asymmetric Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/446,328 external-priority patent/US8653090B2/en
Application filed by Asymmetric Therapeutics LLC filed Critical Asymmetric Therapeutics LLC
Publication of CN104394872A publication Critical patent/CN104394872A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380031029.XA 2012-04-13 2013-04-12 用于治疗与癌症化学治疗剂的给药相关的副作用的组合物和方法 Pending CN104394872A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/446,328 US8653090B2 (en) 2008-03-12 2012-04-13 Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents
US13/446,328 2012-04-13
PCT/US2013/036326 WO2013155385A1 (en) 2012-04-13 2013-04-12 Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents

Publications (1)

Publication Number Publication Date
CN104394872A true CN104394872A (zh) 2015-03-04

Family

ID=49328189

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380031029.XA Pending CN104394872A (zh) 2012-04-13 2013-04-12 用于治疗与癌症化学治疗剂的给药相关的副作用的组合物和方法

Country Status (5)

Country Link
EP (1) EP2836217A4 (enExample)
JP (1) JP2015518000A (enExample)
CN (1) CN104394872A (enExample)
IN (1) IN2014DN09546A (enExample)
WO (1) WO2013155385A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10736557B2 (en) 2016-03-30 2020-08-11 Brain F.I.T. Imaging, LLC Methods and magnetic imaging devices to inventory human brain cortical function
CA3077705A1 (en) 2017-10-03 2019-04-11 Braint F.I.T. Imaging, Llc Methods and magnetic imaging devices to inventory human brain cortical function
WO2020202105A1 (en) 2019-04-03 2020-10-08 Brain F.I.T. Imaging, LLC Methods and magnetic imaging devices to inventory human brain cortical function

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6130035A (en) * 1998-02-20 2000-10-10 Brusilow Enterprise Llc Use of orotidine monophosphate decarboxylase inhibition in a method for cancer screening
WO2005077365A2 (en) * 2004-02-12 2005-08-25 Istituto Superiore di Sanità Novel uses for proton pump inhibitors
US20110077260A1 (en) * 2002-02-12 2011-03-31 Ford John P Methods, compositions, and kits for organ protection during systemic anticancer therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979688B2 (en) * 2002-02-12 2005-12-27 Ford John P Treatment method against side-effects of chemotherapy
US8034823B2 (en) * 2005-02-22 2011-10-11 Savvipharm Inc Method of increasing drug oral bioavailability and compositions of less toxic orotate salts
US7470672B2 (en) * 2006-07-31 2008-12-30 Savvipharm Inc. Compositions and methods of reducing tissue levels of drugs when given as orotate derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6130035A (en) * 1998-02-20 2000-10-10 Brusilow Enterprise Llc Use of orotidine monophosphate decarboxylase inhibition in a method for cancer screening
US20110077260A1 (en) * 2002-02-12 2011-03-31 Ford John P Methods, compositions, and kits for organ protection during systemic anticancer therapy
WO2005077365A2 (en) * 2004-02-12 2005-08-25 Istituto Superiore di Sanità Novel uses for proton pump inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LIAN, T. 等: "Trends and developments in liposome drug delivery systems", 《JOURNAL OF PHARMACEUTICAL SCIENCES》 *
VERMA等: "Osmotically controlled oral drug delivery", 《DEVELOPMENT AND INDUSTRIAL PHARMACY》 *

Also Published As

Publication number Publication date
WO2013155385A1 (en) 2013-10-17
EP2836217A1 (en) 2015-02-18
EP2836217A4 (en) 2015-10-28
IN2014DN09546A (enExample) 2015-07-17
JP2015518000A (ja) 2015-06-25

Similar Documents

Publication Publication Date Title
US20230255995A1 (en) Nicotinyl Riboside Compounds and Their Uses
US11077078B2 (en) Compositions and methods for the treatment of cancer
EP3154590B1 (en) Combination therapy with glutaminase inhibitors
US6579857B1 (en) Combination cancer therapy comprising adenosine and deaminase enzyme inhibitors
EP2262478B1 (en) Activated nitric oxide donors and methods of making and using thereof
RS58609B1 (sr) Kombinovana terapija sa inhibitorom mitoze
WO2006080327A1 (ja) α，α，α－トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤
AU2010208062B2 (en) Compositions and methods for the treatment of cancer
US8653090B2 (en) Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents
US9764029B2 (en) Tumor proliferation inhibitor containing ultrasound-sensitive substance and method for inhibiting tumor proliferation by using tumor proliferation inhibitor and low-intensity pulsed ultrasound waves
US10828271B2 (en) Method for treating pleuroperitoneal membrane cancers by locally injecting disulfiram preparation
US9119855B2 (en) Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents
CN104394872A (zh) 用于治疗与癌症化学治疗剂的给药相关的副作用的组合物和方法
US20090232884A1 (en) Composition and method for treatment of the side-effects associated with administration of cancer chemotherapeutic agents
ES2842376T3 (es) Composición farmacéutica con capecitabina, gimeracil y oteracil para tratar el cáncer, y uso de la misma
CN113893256A (zh) 化合物或其可药用盐、二聚体或三聚体在制备治疗癌症的药物中的应用
CN102014895A (zh) 组合抗癌剂
MXPA06014477A (es) Agente antitumor, fortificador de efecto antitumor y metodo de terapia para cancer.
Wagner et al. Liposome dependent delivery of S‐adenosyl Methionine to cells by liposomes: A potential treatment for liver disease
WO2025093572A1 (en) Solid dispersion compositions and uses thereof
RU2482855C2 (ru) Противоопухолевое средство, включающее производное цитидина и карбоплатин
US20060024376A1 (en) Methods and compositions for reducing toxicity associated with leflunomide treatment
AU2006221479A1 (en) Method of treating liver cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150304

WD01 Invention patent application deemed withdrawn after publication